Association between baseline blood pressure and the incidence of lenvatinib‐induced hypertension in patients with thyroid cancer
Y Shibutani, K Tajiri, S Suzuki, T Enokida… - Cancer …, 2023 - Wiley Online Library
Background Hypertension is the most frequently occurring adverse event of lenvatinib,
recognized relatively early in its course. However, the trend in blood pressure after the …
recognized relatively early in its course. However, the trend in blood pressure after the …
The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity
C Masaki, J Shioya, K Sugino, Y Terasawa… - Supportive Care in …, 2023 - Springer
Purpose Lenvatinib (LEN) is a multikinase inhibitor that strongly inhibits tyrosine kinase
receptors, especially VEGFR-2, which can cause hypertension, as well as strong tumor …
receptors, especially VEGFR-2, which can cause hypertension, as well as strong tumor …